Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
CytomX Therapeutics, Inc. (CTMX) had Consolidated Net Income/Loss of $-0.15M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$18.66M |
|
$-0.15M |
|
-- |
|
$18.66M |
|
$19.94M |
|
$-1.29M |
|
$1.20M |
|
$-0.09M |
|
$-0.09M |
|
$-0.15M |
|
$-0.15M |
|
|
Consolidated Net Income/Loss |
$-0.15M |
$-0.15M |
|
$-1.29M |
|
$-1.34M |
|
129.08M |
|
129.08M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$164.62M |
|
$1.95M |
|
$10.44M |
|
$175.06M |
|
$39.22M |
|
-- |
|
$15.92M |
|
$55.15M |
|
$119.91M |
|
$118.45M |
|
$119.91M |
|
164.91M |
|
| Cash Flow Statement Financials | |
$-36.80M |
|
$-45.76M |
|
$93.55M |
|
$39.08M |
|
$50.07M |
|
$10.99M |
|
$3.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-6.89% |
|
-6.89% |
|
-- |
|
-0.49% |
|
-0.83% |
|
$-36.94M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
-- |
|
9.98 |
|
9.02 |
|
-0.13% |
|
-0.13% |
|
-0.09% |
|
-0.13% |
|
$0.73 |
|
$-0.29 |
|
$-0.29 |
|